OBJECTIVE: Monogenic diabetes (MD) is rare and can often be confused with type 1 diabetes (T1D) in a pediatric cohort. We sought to determine clinical criteria that could optimally identify candidates for genetic testing of two common forms of MD that alter therapy: glucokinase (GCK) and hepatocyte nuclear factor 1 alpha (HNF1α). RESEARCH DESIGN AND METHODS: We performed a retrospective chart review of 939 patients with a presumed diagnosis of T1D, 6 months-20 yr of age, and identified four clinical criteria that were unusual for T1D and could warrant further evaluation for MD: (i) negative pancreatic autoantibodies, (ii) evidence of prolonged endogenous insulin production, or (iii) strong family history of diabetes in multiple generations. One hundred and twenty-one patients were identified as having one or more of these high-risk clinical criteria and were offered screening for mutations in GCK and HNF1α; 58 consented for genetic testing. RESULTS: Of 58 patients with presumed T1D who underwent genetic testing, four were found to have GCK and one had HNF1α. No patients with only one high-risk feature were found to have MD. Of 10 patients who had two or more high risk criteria, five had MD (50%). CONCLUSION: A high frequency of MD from mutations in GCK/HNF1α may be identified among pediatric diabetic patients originally considered to have T1D by performing genetic testing on those patients with multiple clinical risk factors for MD.
OBJECTIVE: Monogenic diabetes (MD) is rare and can often be confused with type 1 diabetes (T1D) in a pediatric cohort. We sought to determine clinical criteria that could optimally identify candidates for genetic testing of two common forms of MD that alter therapy: glucokinase (GCK) and hepatocyte nuclear factor 1 alpha (HNF1α). RESEARCH DESIGN AND METHODS: We performed a retrospective chart review of 939 patients with a presumed diagnosis of T1D, 6 months-20 yr of age, and identified four clinical criteria that were unusual for T1D and could warrant further evaluation for MD: (i) negative pancreatic autoantibodies, (ii) evidence of prolonged endogenous insulin production, or (iii) strong family history of diabetes in multiple generations. One hundred and twenty-one patients were identified as having one or more of these high-risk clinical criteria and were offered screening for mutations in GCK and HNF1α; 58 consented for genetic testing. RESULTS: Of 58 patients with presumed T1D who underwent genetic testing, four were found to have GCK and one had HNF1α. No patients with only one high-risk feature were found to have MD. Of 10 patients who had two or more high risk criteria, five had MD (50%). CONCLUSION: A high frequency of MD from mutations in GCK/HNF1α may be identified among pediatric diabeticpatients originally considered to have T1D by performing genetic testing on those patients with multiple clinical risk factors for MD.
Authors: E Kawasaki; Y Sera; K Yamakawa; T Abe; M Ozaki; S Uotani; N Ohtsu; H Takino; H Yamasaki; Y Yamaguchi; N Matsuura; K Eguchi Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: S Yamada; H Nishigori; H Onda; T Utsugi; T Yanagawa; T Maruyama; K Onigata; K Nagashima; R Nagai; A Morikawa; T Takeuchi; J Takeda Journal: Diabetes Date: 1997-10 Impact factor: 9.461
Authors: A Paul Lambert; Sian Ellard; Lisa I S Allen; Ian W Gallen; Kathleen M Gillespie; Polly J Bingley; Andrew T Hattersley Journal: Diabetes Care Date: 2003-02 Impact factor: 19.112
Authors: Shideh Majidi; Alexandra Fouts; Laura Pyle; Christina Chambers; Taylor Armstrong; Zhenyuan Wang; Sat Dev Batish; Georgeanna Klingensmith; Andrea K Steck Journal: Diabetes Technol Ther Date: 2018-02 Impact factor: 6.118
Authors: Beverley M Shields; Maggie Shepherd; Michelle Hudson; Timothy J McDonald; Kevin Colclough; Jaime Peters; Bridget Knight; Chris Hyde; Sian Ellard; Ewan R Pearson; Andrew T Hattersley Journal: Diabetes Care Date: 2017-08 Impact factor: 19.112
Authors: Maggie Shepherd; Beverley Shields; Suzanne Hammersley; Michelle Hudson; Timothy J McDonald; Kevin Colclough; Richard A Oram; Bridget Knight; Christopher Hyde; Julian Cox; Katherine Mallam; Christopher Moudiotis; Rebecca Smith; Barbara Fraser; Simon Robertson; Stephen Greene; Sian Ellard; Ewan R Pearson; Andrew T Hattersley Journal: Diabetes Care Date: 2016-06-06 Impact factor: 19.112
Authors: Christina Chambers; Alexandra Fouts; Fran Dong; Kevin Colclough; Zhenyuan Wang; Sat Dev Batish; Malgorzata Jaremko; Sian Ellard; Andrew T Hattersley; Georgeanna Klingensmith; Andrea K Steck Journal: Pediatr Diabetes Date: 2015-06-08 Impact factor: 4.866
Authors: H Yaghootkar; F Abbasi; N Ghaemi; A Rabbani; M N Wakeling; P Eshraghi; S Enayati; S Vakili; S Heidari; K Patel; F Sayarifard; S Borhan-Dayani; T J McDonald; S Ellard; A T Hattersley; M M Amoli; R Vakili; K Colclough Journal: Diabet Med Date: 2019-07-25 Impact factor: 4.359
Authors: Maggie H Shepherd; Beverley M Shields; Michelle Hudson; Ewan R Pearson; Christopher Hyde; Sian Ellard; Andrew T Hattersley; Kashyap A Patel Journal: Diabetologia Date: 2018-09-18 Impact factor: 10.122